Role of taxanes

Breast Cancer Research and Treatment

Volumn 81, Issue SUPPL. 1, 2003, Pages

  Petruzelka, Lubos ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Chemotherapy; Docetaxel; Metastatic breast cancer; Paclitaxel

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOMYCIN; PACLITAXEL; PREDNISONE; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

ALOPECIA; ARTHRALGIA; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG DOSE REGIMEN; DRUG RESPONSE; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY REACTION; METASTASIS; MONOTHERAPY; MYALGIA; NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; STOMATITIS;

EID: 0344441844     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1026356520714     Document Type: Conference Paper

References (33)

1. Peretz T, Sulkert A, Challet R et al.: A multicenter, randomised study of two schedules of paclitaxel in patients with advanced breast cancer. Proc Eur J Cancer 31A: S75, 1995 (Abstract 480)
2. Nabholtz JM, Gelman K, Bontenbal et al.: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858-1867, 1996
3. Holmes FA, Valero V, Buzdar A et al.: Final results: randomized phase III trials of paclitaxel by 3-hr versus 96-hr infusion in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 17: 110a, 1998 (Abstract 426)
4. Winer E, Berry D, Duggan D et al.: Failure of higher dose paclitaxel to improve outcome in patients with metastastic breast cancer - results from CALGB 9342. Proc Am Soc Clin Oncol 17: 101a, 1998 (Abstract 389)
5. Smith RE, Brown AM, Mamounas EP et al.: Randomized trial of 3-hour versus 24-hour infusion of high dose paclitaxel in patients with metastatic or locally advanced breast cancer: NSABP Protocol B-26. J Clin Oncol 17: 3403-3411, 1999
6. Nabholtz JM, Tonkin MK: Taxanes: paclitaxel and docetaxel. In: Nabholtz JM, Tonkin K, Aapro M (eds), Breast Cancer Management. Application of Evidence to Patient Care. AU Buzdar, Martin Dunitz Ltd., 2000
7. Hudis CA, Seidman AD, Crown JPA et al.: Phase II and pharmacological study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14: 58-65, 1996
8. Chevallier B, Fumoleau P, Kerbat P et al.: Docetaxel is a major cytotoxic drug for treatment of advanced breast cancer: a phase II study of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314-322, 1995
9. Valero V, Holmes FA, Walters RS et al.: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886-2894, 1995
10. 2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer 74: 650-656, 1996
11. O'Brien MER, Leonard RCF, Barrett-Lee PJ et al.: Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (taxotere) in the UK. Ann Oncol 10: 205-210, 1999
12. Adachi I, Watanabe T, Takashima S et al.: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent cancer. Br Cancer 73: 210-216, 1996
13. Burstein HJ, Bunnell CA, Winer EP: New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol 28: 344-358, 2001
14. 2 as second line chemotherapy in advanced breast cancer. SABCC, San Antonio, Texas, 2002 (Abstract 32)
15. Bonnettere J, Roche H, Monnier A et al.: Taxotere versus 5-fluorouracil plus Navelbine as second line chemotherapy with metastatic breast cancer. Proc Am Soc Clin Oncol 16: 162a. 1997
16. Nabholtz JM, Senn JH, Bezwoda WR et al.: Prospective randomised trial of docetaxel versus mitomycin plus vinblastin in patients with metastatic breast cancer progressing despite previous anthracycline-containing therapy. J Clin Oncol 17: 1413-1424, 1999
17. Sjostrom J, Blomqvist C, Mouridsen H et al.: Docetaxel compared with sequential methotrexate-5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase II study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194-1201, 1999
18. Perez EA, Vogel CL, Irwin DH et al.: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19: 4216-4223, 2001
19. Chan S, Friedrichs K, Noel D et al. for the 303 Study Group: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341-2354, 1999
20. Paridaens R, Biganzoli L, Bruning P et al. for the EORTC-Investigational Drug Branch for Breast Cancer/Early Clinical Studies Group: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 18: 724-733, 2000
21. Sledge GW, Neuberg D, Ingle J et al.: Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an Intergroup trial. Am Soc Clin Oncol 16: 1a, 1997 (Abstract)
22. Bishop J, Dewar J, Toner G et al.: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 17: 2355-2364, 1999
23. Gamucci T, Piccard M, Brunning P et al.: Single-agent taxol (T) versus doxorubicin(D) as first-and second-line chemotherapy (CT) in advanced breast cancer (ABC): final results of an EORTC randomized study with crossover. Proc Am Soc Clin Oncol 17: 111, 1998 (Abstract 428)
24. Bonneterre J, Dieras V, Tubiana-Hulin M et al.: 6 cycles of epirubicin/docetaxel (ET) versus 6 cycles of 5FU epirubicin/cyclophosphamide (FEC) as first line metastatic breast cancer (MBC) treatment. Proc Am Soc Clin Oncol 20: 42a, 2001 (Abstract 163)
25. Nabholtz JM, Falkson G, Campos D et al.: A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC. Proc Am Soc Clin Oncol 18: 127a, 1999 (Abstract 485)
26. Nabholtz JA, Paterson A, Dirix L et al.: Phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) (TAC) to FAC as first line chemotherapy (CT) for patients (ps) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20: 22a, 2001 (Abstract 83)
27. Biganzoli L, Cufer T, Bruning P et al.: Doxorubicin (A)/taxol (T) versus doxorubicin/cyclophosphamide (C) as first line chemotherapy in metastatic breast cancer (MBC): a phase III study. Proc Am Soc Clin Oncol 19: 73a, 2000 (Abstract 282)
28. Jassem J, Pienkowski T, Pluzanska A et al. for the Central and Eastern Europe and Israel Paclitaxel Breast Cancer Study Group: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19: 1707-1715, 2001
29. Lück HJ, Thomssen C, Untch M et al.: Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proc Am Soc Clin Oncol 19: 73a, 2000 (Abstract 280)
30. Carmichael J: UKCCCR trial of epirubicin and cyclophosphamide (EC) vs. epirubicin and taxol® (ET) in the first line treatment of women with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20: 22a, 2001 (Abstract 84)
31. Nabholtz KM, Reese DM, Lindsay MA, Riva A: Docetaxel in the treatment of breast cancer: an update on recent studies. Sem Oncol 29(Suppl 12): 28-34, 2002
32. O'Shaughnessy J, Miles D, Vukelja S et al.: Superior survival with capecitabine plus docetaxel combination-therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823, 2002
33. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001